Cingulate Inc (CING) Stock Price, Quote & News

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1...

Industry: Biotechnology

Sector: Healthcare

Phone: 913 942 2300

Website: www.cingulate.com

Address:

1901 West 47th Place, Kansas City, United States

Peppe1986 Dec. 4 at 9:03 PM

$CING This GARBAGE AFTER PATENT .. will be the $SMX … $CING this s… have the power to fly , and u will feel the smell everywhere !!!!!!!!!

1 · Reply

DonkeyClanbrands Dec. 3 at 7:24 PM

$CING watch this my gift of the day https://youtu.be/CJcH-n6iKVU

0 · Reply

DonkeyClanbrands Dec. 3 at 5:42 PM

$CING wish we had more banter here ;)

2 · Reply

activehybrid Dec. 3 at 6:08 AM

$CING does anyone know how they calculate long and short volumes ? If long volume is higher than short volume, price should increase, right ?

0 · Reply

sam9420 Dec. 3 at 2:30 AM

$CING over night price 4.20 $ 🔥🔥🔥

2 · Reply

stockpurrrrs Dec. 2 at 7:21 PM

$CING added!

0 · Reply

Peppe1986 Dec. 2 at 7:01 PM

$CING Never … is a good stock with s…. Management … very sad …

1 · Reply

MOOSEN Dec. 2 at 7:00 PM

$CING 3.84 STARTER.

1 · Reply

sam9420 Dec. 2 at 5:56 PM

$CING when we can see 15$ here ?!

1 · Reply

TheSuper Dec. 2 at 5:10 PM

$CING Added as well.

1 · Reply

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Oct 23, 2025, 4:45 PM EDT - 6 weeks ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Sep 17, 2025, 8:45 AM EDT - 2 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Aug 21, 2025, 4:35 PM EDT - 3 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 19, 2025, 8:45 AM EDT - 3 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 15, 2025, 9:00 AM EDT - 3 months ago

Cingulate Provides Management Team Update

Aug 6, 2025, 8:45 AM EDT - 4 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Jun 18, 2025, 8:00 AM EDT - 6 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

May 8, 2025, 4:30 PM EDT - 7 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Apr 9, 2025, 8:00 AM EDT - 8 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Mar 26, 2025, 5:00 PM EDT - 9 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Mar 6, 2024, 6:45 AM EST - 1 year ago

Cingulate to Attend DCAT Week 2024 in New York City

Feb 13, 2024, 6:45 AM EST - 1 year ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 6, 2024, 4:15 PM EST - 1 year ago

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 1 year ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

Peppe1986 Dec. 4 at 9:03 PM

$CING This GARBAGE AFTER PATENT .. will be the $SMX … $CING this s… have the power to fly , and u will feel the smell everywhere !!!!!!!!!

1 · Reply

DonkeyClanbrands Dec. 3 at 7:24 PM

$CING watch this my gift of the day https://youtu.be/CJcH-n6iKVU

0 · Reply

DonkeyClanbrands Dec. 3 at 5:42 PM

$CING wish we had more banter here ;)

2 · Reply

activehybrid Dec. 3 at 6:08 AM

$CING does anyone know how they calculate long and short volumes ? If long volume is higher than short volume, price should increase, right ?

0 · Reply

sam9420 Dec. 3 at 2:30 AM

$CING over night price 4.20 $ 🔥🔥🔥

2 · Reply

stockpurrrrs Dec. 2 at 7:21 PM

$CING added!

0 · Reply

Peppe1986 Dec. 2 at 7:01 PM

$CING Never … is a good stock with s…. Management … very sad …

1 · Reply

MOOSEN Dec. 2 at 7:00 PM

$CING 3.84 STARTER.

1 · Reply

sam9420 Dec. 2 at 5:56 PM

$CING when we can see 15$ here ?!

1 · Reply

TheSuper Dec. 2 at 5:10 PM

$CING Added as well.

1 · Reply

Learningtoberich Dec. 2 at 3:03 PM

$CING added a position here. Let's ride

1 · Reply

Ron_Burn Dec. 1 at 11:11 AM

$CING breakout pattern. It has been a long journey to here, don't bail out just yet...

1 · Reply

Peppe1986 Nov. 29 at 4:18 PM

$CING Any need from this shittt ???? Come on …. Put this shittttt to 30-40 $ !!!!!!

0 · Reply

DonkeyClanbrands Nov. 29 at 10:43 AM

$CING as we patiently wait for the patent and FDA I would feel bad if I didnt share my biggest bag with you all to do some DD on. Been accumulating for over 4 years and with biomarker data coming any day (i would be shocked if it wasn’t OUTSTANDING) https://gaintherapeutics.wordpress.com/2025/11/16/gain-therapeuticsganx-updated-analyst-reports-with-all-eyes-on-biomarker-readout-in-q4/

0 · Reply

ZacksResearch Nov. 28 at 6:31 PM

$CING Gains 5% in a Month 🚀 The FDA accepted the NDA for CTx-1301 with a May 31, 2026 PDUFA date, Phase 3 data hit its primary endpoint, and the company brought in a seasoned commercial leader alongside a $6M financing to prep for a potential launch. Plus, they locked in a commercial supply deal and secured a $4.3M PDUFA fee waiver — a meaningful boost to the balance sheet. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/CING/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-22798&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_22798

0 · Reply

fullobullz Nov. 27 at 5:40 PM

$CING Happy Thanksgiving $CING longs. Patent news is just around the corner

1 · Reply

activehybrid Nov. 25 at 5:55 AM

$CING I’m checking cingulate site and Shane Schafer personal site everyday if anything changes Shane’s site was not reachable yesterday interestingly and today main page is like “chairman and ceo of cingulate “ on top of of main page Maybe it’s just a coincidence!

0 · Reply

fullobullz Nov. 20 at 9:53 PM

$CING looks like he got 180 days in county and 1 year probation. Looks like its still felony too.

3 · Reply

StarStripedBass77 Nov. 20 at 6:23 PM

$CING feels like we’re about to move up..

0 · Reply

Jumpingfox Nov. 20 at 3:16 PM

$CING Roth Capitol has an average price target of $31 SP and up to $61. https://www.nasdaq.com/articles/roth-capital-maintains-cingulate-cing-buy-recommendation-0

0 · Reply

fullobullz Nov. 20 at 3:13 PM

$CING Shane has hearing today to get charges dropped to misdemeanor.

1 · Reply

Peppe1986 Nov. 19 at 10:29 PM

$IXHL $CING …. At least u will not lose all your money , is another shit … but with more possibility of success… Joel is a f… maricon and a scammer , and no one of u … speak with him … good luck … to me 😁

1 · Reply

Market Cap	26.29M
Revenue (ttm)	0.00
Net Income (ttm)	-15.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	137,400
Avg Vol	178,764
Day's Range	N/A - N/A
Shares Out	6.76M
Stochastic %K	92%
Beta	-0.74
Analysts	Strong Sell
Price Target	$28.20